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ABSTRACT
Since the definition of the degradome as the com-
plete repertoire of proteases in a given organism,
the combined effort of numerous laboratories has
greatly expanded our knowledge of its roles in biol-
ogy and pathology. Once the genomic sequences of
several important model organisms were made avail-
able, we presented the Degradome database con-
taining the curated sets of known protease genes
in human, chimpanzee, mouse and rat. Here, we de-
scribe the updated Degradome database, featuring
81 new protease genes and 7 new protease fami-
lies. Notably, in this short time span, the number of
known hereditary diseases caused by mutations in
protease genes has increased from 77 to 119. This
increase reflects the growing interest on the roles
of the degradome in multiple diseases, including
cancer and ageing. Finally, we have leveraged the
widespread adoption of new webtools to provide in-
teractive graphic views that show information about
proteases in the global context of the degradome.
The Degradome database can be accessed through
its web interface at http://degradome.uniovi.es.
INTRODUCTION
Proteases catalyze the hydrolysis of peptide bonds in a fun-
damentally irreversible reaction. This means that these en-
zymes must be tightly regulated in terms of activation and
specificity to avoid massive homeostatic disorders. In turn,
this need for specificity has led to the evolutionary expan-
sion of protease genes to regulate the correct proteolysis of
a large set of substrates. The parallel expansion of protease
inhibitor genes added an additional level of complexity to
this biochemical process. In recognition of this complex and
interwoven system, the degradome of an organism was de-
fined as the complete set of proteases in that organism (1).
The degradome has been shown to affect most of the char-
acterized biochemical pathways. Thus, different proteases
are known to play key roles in such biological processes
as cell cycle progression, tissue remodelling, neuronal out-
growth, haemostasis, wound healing, immunity, angiogen-
esis and apoptosis (2–6). Conversely, failures in the regula-
tion of the degradome underlie diverse pathological condi-
tions, including cancer, arthritis, progeria and neurological
diseases (7–10).
Since the definition of the degradome relies on a global
appraisal of the proteolytic processes, it follows that de-
gradomics, the set of techniques specifically aimed at char-
acterizing the degradome, must manage and integrate high-
throughput data. In this regard, the completion of multi-
ple genome projects allowed researchers to extend the de-
gradomes of several species in silico from known protease
sequences (11,12). Our experience in degradomics led us
to tackle this problem with methods that relied heavily on
manual curation after automatic predictions (13). As an ad-
ditional advantage of this approach, a part of these projects
consisted in the mining of the literature looking for known
relationships between protease alterations and hereditary
diseases, termed degradomopathies.
With this information, we described the Degradome
database, containing the results of themanual annotation of
every protease gene in the genomes of human, chimpanzee,
mouse, and rat, along with relationships between protease
alterations and hereditary diseases (14). This database com-
plemented existing databases devoted to proteases, by pro-
viding a different focus. For instance, CutDB documents
actual and predicted proteolytic events, but does not pro-
vide a global view of the proteases themselves (15). Also,
MEROPS is a comprehensive and excellent database which
relies on large-scale experiments and automatic predictions
(16). By contrast, the Degradome database relies on man-
ual annotation and exhaustive curation of genes, inmultiple
cases supported by direct cloning and sequencing experi-
ments. For this reason, multiple instances of non-functional
gene expansions, which our approach has filtered out, are
annotated as putative proteases in the MEROPS database.
In fact, the number of putative human proteases according
to MEROPS is 990, whereas the Degradome database de-
scribes 588. In exchange, the MEROPS database features a
very large number of species. Finally, our emphasis in dis-
eases adds important information on the pathological rel-
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Figure 1. New annotations of proteases and degradomopathies. The num-
ber of proteases and degradomopathies annotated in each catalytic class is
represented at the time of creation of the database (2009) and at the current
version (2015).
evance of some proteases, which is not directly available
in other databases. In our view, these databases taken to-
gether provide an accurate depiction of the current knowl-
edge about degradomics.
In these last years, the field of degradomics has experi-
enced a remarkable expansion, not so much in the num-
ber of known proteases as in the biological and patholog-
ical roles played by the degradome. Thus, almost all of the
growth in the number of known proteases has developed
through the inclusion of new protein families which were
not previously known to display proteolytic activity. This
suggests that the initial annotation of proteases in these
model genomes was highly successful. However, the num-
ber of known degradomopathies has undergone a sharp in-
crease (>50%) in the last six years. In this manuscript, we
present the updates to the Degradome database, including
new interactive representations which, in our opinion, pro-
vide a useful global depiction of the degradomes.
DATABASE ACCESS
Annotation of individual proteases
The overall organization of the database remains un-
changed, with information about five catalytic classes
(aspartyl-, cysteine-, metallo-, serine- and threonine-
proteases) encompassing 82 protease families in four
species. Compared to the previous version of this database,
we have annotated seven additional families with 18 new
human and chimpanzee proteases, 21 new mouse proteases
and 17 new rat proteases (Figure 1). This growth reflects
a body of biochemical research by multiple laboratories
which has uncovered previously unknown proteolytic activ-
ities in known proteins (17–19).
The first mode of access is contained in five tables, one
for each catalytic class. Each table displays the names of the
protease families using the MEROPS classification system,
the name of each protease, and the gene symbol for the pro-
tease in each species (Figure 2A). The table directly repre-
sents the orthology between proteases in different species, as
well as the pseudogenes for which a functional ortholog ex-
ists in at least one of the selected mammalian species. Click-
ing each table cell gives the user access to additional infor-
mation. Thus, the family name leads to a summary con-
taining selected publications about that family of proteases,
and, when available, a description of its structural features.
In addition, protease-specific links open popup tables with
information about the status and activity of each protease
and, if available, hyperlinks to other databases, including
MEROPS (16), NCBI Gene (20) and Ensembl (21). These
tables also show if the protease is involved in a degrado-
mopathy, along with a link to the OMIM database entry
describing the disease.
Hereditary diseases of proteolysis
The information about mutated proteases in hereditary dis-
eases is kept into a separate table (http://degradome.uniovi.
es/diseases.html), to bypass the need to browse or search
the individual annotations. This table of degradomopathies
contains information about causal gene locus, mode of in-
heritance, pathologic protease alteration (gain/loss of pro-
teolytic activity), and availability of described animal mod-
els containing the same protease anomaly. A link to related
OMIM entries is also provided.
To our knowledge, this remains the only summary of the
relationships between degradomics and pathology. In six
years, the number of entries has grown from 77 to 119, re-
flecting the intense research into the pathological implica-
tions of the degradome. In fact, several proteases, such as
ADAM10 and AFG3L2, have been related to more than
one hereditary disease through different alterations. This ta-
ble does not reflect thewhole contribution of the degradome
to human disease, as it does not encompass the numerous
examples of non-hereditary diseases in which proteases are
known to play an important role through alterations in their
spatio-temporal patterns of expression. In this regard, the
Degradome database has also demonstrated its usefulness
in the analysis of proteases associated with cancer (22,23)
and ageing (4,24).
Graphic interface
Ever since its definition, a recurrent global representation of
the degradome has featured a characteristic circular draw-
ing (Figure 2B). In this new version of the Degradome
database, we have developed a tool that depicts the whole
database as an svg figure. In addition to being customiz-
able and constantly updated, this format allows a fair level
of interaction with the user. Thus, each individual protease
object contains a hyperlink to the corresponding annota-
tion table. This figure can also be modified to represent the
results of a search.
More importantly, this figure provides a global view of
the degradomes of the included species. This not only pro-
vides a sense of the sizes of protease families, but also a fast
and intuitive comparison between the degradomes of differ-
ent species, including family expansions (i.e. mouse and rat
expansions of the S01 family) and pseudogenization events.
This interactive figure is used at this time in the home page
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Figure 2. New features of the Degradome database. (A) Individual annotations of aspartyl proteases. The first column contains the name of the family,
with a hyperlink to a web page where the user can find related selected publications and structures. The second column contains the name of each protease,
with a hyperlink which opens a popup table with further general information––in this example, presenilin 1. Pseudogenes are shown over a pink background.
Proteases absent in a species are shown as empty grey cells. (B) Interactive representation of the degradomes of (from outer to inner ticks) human, chim-
panzee, mouse and rat. Protease families are limited with black and white boxes. Catalytic classes are shown as background colored arcs. Proteases which
have been pseudogenized are depicted as blue ticks, and proteases absent in an organism are shown as grey ticks. Human collagenase-3 is highlighted to
show the interactivity of the ticks.
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(http://degradome.uniovi.es/dindex.html), as an alternative
entry method for the database, and as a snapshot of the
differences between the degradomes of human and mouse
(http://degradome.uniovi.es/hmd.html).
Additional contents
In addition to the Degradome database, the web site also
keeps offering several summaries of the characteristics of
mammalian degradomes. Thus, a static table listing hu-
man, mouse and rat protease inhibitors can be found at
http://degradome.uniovi.es/inhibitors.html. A count of pro-
teases in these species, itemized by catalytic class, is shown at
http://degradome.uniovi.es/numbers.html. These numbers
are kept updated as novel catalytic classes are discovered
and added to the Degradome database. Additionally, we
also keep a figure showing the different ancillary domains
present in proteases (http://degradome.uniovi.es/domains.
html). Interactive structures for different protease families
are also kept in pdf format for teaching purposes (http:
//degradome.uniovi.es/structures.html).
IMPLEMENTATION
The database with the annotations of individual proteases
has been migrated to a single JSON file, which is freely
available upon request. The information is queried from the
web interface using the AJAX technology through JQuery.
Therefore, if the browser lacks Javascript or Javascript is
blocked, the user is offered a link to a static table displaying
all of the information at once. The style of the web pages is
implemented with the Bootstrap library to increase acces-
sibility from multiple devices. The new graphical interface
is written in svg, which is directly generated from the de-
gradome JSON file using a custom Perl script.
Finally, selected structures are displayed in pdf format.
Thus, the user needs Adobe Reader v7.0 or higher. Sev-
eral reasons may hamper the viewing for these files from the
common browsers. If this happens, the user can download
the pdf file and access its contents locally.
CONCLUSION AND FUTURE DIRECTION
The Degradome database has grown in the last years re-
flecting the advances in our understanding of proteases in
biological and pathological processes. As a part of our in-
volvement in degradomics, we will continue updating this
database as more results become available. Based on our ex-
perience, we expect this increase to continue, driven mainly
by two sources: biochemical studies that uncover novel pro-
teolytic activities and high-throughput association studies
which relate additional protease mutations with hereditary
diseases.
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